Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Melanoma 1Brain Neoplasms 1

Interventions

Bevacizumab 4Specimen Handling 2Everolimus 2Biopsy 2trametinib 1relatlimab 1pembrolizumab 1lutetium Lu 177 dotatate 1fluoromisonidazole 1fludarabine phosphate 1antineoplaston AS 2-1 1antineoplaston A10 1aldesleukin 1X-Rays 1Transcranial Magnetic Stimulation 1TPI-287 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sunitinib 1Radiosurgery 1Nivolumab 1Niacinamide 1Niacin 1Metformin 1Mental Status and Dementia Tests 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Lomustine 1Lasers, Solid-State 1Lasers 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × CA-4948 × CNS × Clear all
NCT05669352 2025-04-04

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

University of Florida

Phase 1/2 Suspended
29 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡